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background: The angiotensin receptor nepriliysin inhibitor, reduces NT-proBNP, left atrial (LA) size and improves NYHA class in patients with heart 
failure with preserved ejection fraction (HFpEF). We examined whether these effects were independent of systolic blood pressure (SBP) lowering.
Methods: In the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) trial 301 
patients were randomized to LCZ696 or valsartan. We examined the relationship between SBP lowering and LCZ696 on NT-proBNP level, LA size, New 
York Heart Association (NYHA) class and estimated glomerular filtration rate (eGFR).
results: Change in NT-proBNP was poorly correlated with change in SBP (LCZ696, r=0.17, P= 0.06, valsartan,r=0.05, P=0.58) After adjustment for 
change in SBP, the ratio of change in NT-proBNP at 12 weeks for LCZ696 versus valsartan was 0.76(95%CI 0.63-0.93), P=0.008; unadjusted =0.77 
95%CI 0.64-0.92; P=0.005. There was no difference by tertile of change in SBP, tertile 1, 1 to 61 mmHg change (0.75 95%CI 0.54-1.03), tertile 2, 
-11 to 0 mmHg change (0.69 95%CI 0.48-1.01), tertile 3, -48 to -12 mmHg change (0.62 95%CI 0.88-1.25); P for interaction = 0.38. Reduction in 
LA volume index at 36 weeks, improvement in NYHA class and eGFR were all independent of the change in SBP (Table).
conclusions: In patients with HFpEF, the effect of the angiotensin receptor neprilysin inhibitor LCZ696 on NT-proBNP, LA volume, NYHA class and 
eGFR was independent of SBP reduction.
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Overall P LCZ696 vs 
valsartan (adjusted 
for change in SBP at 
36 weeks)
P for 
interaction
Left atrial diameter LCZ696 -0.15(-0.25 to -0.06) -0.12(-0.23 to -0.01) -0.19(-0.32 to -0.05) 0.03 0.91
valsartan -0.04(-0.14 to 0.06) -0.07(-0.16 to 0.02) -0.11(-0.22 to 0.01)
Left atrial indexed 
volume
LCZ696 -2.64 (-4.71 to -0.59) -1.77 (-4.87 to 1.34) -3.74 (-7.18 to -0.29) 0.01 0.61
valsartan -0.28(-3.54 to 2.98) 0.22 (-2.69 to 3.14) 0.80(-2.53 to 4.13)
eGFR LCZ696 -3.83(-6.99 to -0.67) -1.28(-6.26 to 3.70) 1.86(-3.02 to 6.74) 0.002 0.69
valsartan -9.09(-12.78 to -5.41) -3.03(-7.16 to 1.11) 1.52(-7.34 to -1.23)
